Molecular Pharmacology

Papers
(The H4-Index of Molecular Pharmacology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Simplified Method for Kinetic and Thermodynamic Screening of Cardiotonic Steroids through the K+-Dependent Phosphatase Activity of Na+/K+-ATPase with Chromogenic pNPP Substrate58
A 19F-qNMR-Guided Mathematical Model for G Protein-Coupled Receptor Signaling34
Phosphoproteomics-Based Characterization of Prostaglandin E2 Signaling in T Cells32
In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A2A Receptor Antagonist/Inverse Agonist28
Structural Basis for the Allosteric Inhibition of Hypoxia-Inducible Factor 2 by Belzutifan27
Enhancing remyelination in multiple sclerosis via M1 muscarinic acetylcholine receptor26
Fat traffic control: S-acylation in axonal transport26
Current Understanding of Membrane Transporters as Regulators or Targets for Cisplatin-Induced Hearing Loss25
Lysine Demethylase 6B Regulates Prostate Cancer Cell Proliferation by Controlling c-MYC Expression24
CPL207280, a Novel G Protein–Coupled Receptor 40/Free Fatty Acid Receptor 1–Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals23
Isoprenaline shows unique kinase dependencies in stimulating β1AR–β-arrestin2 interaction compared to endogenous catecholamines23
Regulation of organic anion transporting polypeptide 1B1 transport function by concurrent phosphorylation and lysine-acetylation: A novel posttranslational regulation mechanism21
Editorial Board20
Thermogenic Modulation of Adipose Depots: A Perspective on Possible Therapeutic Intervention with Early Cardiorenal Complications of Metabolic Impairment19
Table of Contents19
Editorial Board19
Development of a Novel Assay for Direct Assessment of Selective Amylin Receptor Activation Reveals Novel Differences in Behavior of Selective and Nonselective Peptide Agonists18
Discovery of RGS2-FBXO44 interaction inhibitors using a cell-based NanoBit assay17
0.18697786331177